289 related articles for article (PubMed ID: 38318166)
41. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
42. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
[TBL] [Abstract][Full Text] [Related]
43. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
[TBL] [Abstract][Full Text] [Related]
44. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
[TBL] [Abstract][Full Text] [Related]
45. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
[TBL] [Abstract][Full Text] [Related]
46. Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4
Tye EXC; Jinks E; Haigh TA; Kaul B; Patel P; Parry HM; Newby ML; Crispin M; Kaur N; Moss P; Drennan SJ; Taylor GS; Long HM
Nat Immunol; 2022 Dec; 23(12):1726-1734. PubMed ID: 36456735
[TBL] [Abstract][Full Text] [Related]
47. Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm.
Boni C; Cavazzini D; Bolchi A; Rossi M; Vecchi A; Tiezzi C; Barili V; Fisicaro P; Ferrari C; Ottonello S
Front Immunol; 2021; 12():730051. PubMed ID: 34566990
[TBL] [Abstract][Full Text] [Related]
48. Landscape and selection of vaccine epitopes in SARS-CoV-2.
Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
[TBL] [Abstract][Full Text] [Related]
49. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
Gao Y; Cai C; Grifoni A; Müller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Österborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren HG; Karlsson AC; Sette A; Aleman S; Buggert M
Nat Med; 2022 Mar; 28(3):472-476. PubMed ID: 35042228
[TBL] [Abstract][Full Text] [Related]
50. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
51. Limited Recognition of Highly Conserved Regions of SARS-CoV-2.
Swaminathan S; Lineburg KE; Ambalathingal GR; Crooks P; Grant EJ; Mohan SV; Raju J; Panikkar A; Le Texier L; Tong ZWM; Chew KY; Neller MA; Short KR; Gowda H; Gras S; Khanna R; Smith C
Microbiol Spectr; 2022 Feb; 10(1):e0278021. PubMed ID: 35196796
[TBL] [Abstract][Full Text] [Related]
52. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.
Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141
[TBL] [Abstract][Full Text] [Related]
53. Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8
Wang Y; Yang L; Tang K; Zhang Y; Zhang C; Zhang Y; Jin B; Zhang Y; Zhuang R; Ma Y
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257752
[TBL] [Abstract][Full Text] [Related]
54. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals.
Lang-Meli J; Luxenburger H; Wild K; Karl V; Oberhardt V; Salimi Alizei E; Graeser A; Reinscheid M; Roehlen N; Reeg DB; Giese S; Ciminski K; Götz V; August D; Rieg S; Waller CF; Wengenmayer T; Staudacher D; Huzly D; Bengsch B; Kochs G; Schwemmle M; Emmerich F; Boettler T; Thimme R; Hofmann M; Neumann-Haefelin C
Nat Microbiol; 2022 May; 7(5):675-679. PubMed ID: 35484232
[TBL] [Abstract][Full Text] [Related]
56. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
57. SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.
Schmidt KG; Nganou-Makamdop K; Tenbusch M; El Kenz B; Maier C; Lapuente D; Überla K; Spriewald B; Bergmann S; Harrer EG; Harrer T
Front Immunol; 2021; 12():627568. PubMed ID: 33995351
[TBL] [Abstract][Full Text] [Related]
58. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron.
Ahmed SF; Quadeer AA; McKay MR
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062283
[TBL] [Abstract][Full Text] [Related]
59. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
Tahir Ul Qamar M; Shahid F; Aslam S; Ashfaq UA; Aslam S; Fatima I; Fareed MM; Zohaib A; Chen LL
Infect Dis Poverty; 2020 Sep; 9(1):132. PubMed ID: 32938504
[TBL] [Abstract][Full Text] [Related]
60. Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses.
Wang CY; Peng WJ; Kuo BS; Ho YH; Wang MS; Yang YT; Chang PY; Shen YH; Hwang KP
PLoS Pathog; 2023 Apr; 19(4):e1010870. PubMed ID: 37079651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
